Home › NDC Lookup › RxCUI directory › RxCUI 2054269

{7 (valbenazine 40 MG Oral Capsule [Ingrezza]) / 21 (valbenazine 80 MG Oral Capsule [Ingre... — RxCUI 2054269

RxNorm drug concept · Brand name pack
RxCUI 2054269 Brand name pack · BPCK ● Current RxNorm concept 8 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2054269
Official name{7 (valbenazine 40 MG Oral Capsule [Ingrezza]) / 21 (valbenazine 80 MG Oral Capsule [Ingrezza]) } Pack [Ingrezza]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asINGREZZA 40 MG / 80 MG Starter Pack, 28 capsules; INGREZZA 40 MG / 80 MG Starter Pack
FDA products mapped8
Package NDCs mapped8
Reported Medicaid activity (SDUD)83,640 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Valbenazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Valbenazine is designed to reduce the uncontrolled, involuntary movements that can be really disruptive to daily life. If you have tardive dyskinesia — those repetitive facial or b...
  • What exactly is this medication supposed to do for me?
  • Yes, drowsiness is the most commonly reported side effect — so this is worth planning for. Some people find it quite manageable, while others feel it more strongly, especially when...
  • Yes, and this is really important. Valbenazine carries a serious warning specifically for people with Huntington's disease: it can increase the risk of depression and suicidal thou...
📖 Read our full Valbenazine guide →

🕸️ Concept Web — How {7 (valbenazine 40 MG Oral Capsule [Ingrezza]) /... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {7 (valbenazine 40 MG Oral Capsule [Ingrezza]) / 21 (valbenazine 80 MG Oral Capsule [Ingrezza]) } Pack [Ingrezza] RxCUI 2054269

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Valbenazine 1918219
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ingrezza 1918225
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Valbenazine Oral Capsule 1918223
    • Valbenazine Oral Product 1918221
    • Valbenazine Pill 1918222
    • Valbenazine Oral Capsule [Ingrezza] 1918227
    • Ingrezza Oral Product 1918228
    • Ingrezza Pill 1918229
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

8 products · 8 package NDCs
8 package NDCs map to RxCUI 2054269 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70370-1060-01 30 CAPSULE in 1 BOTTLE (70370-1060-1) INGREZZA Neurocrine Biosciences, Inc. 2021-04-23
70370-1080-01 30 CAPSULE in 1 BOTTLE (70370-1080-1) INGREZZA Neurocrine Biosciences, Inc. 2017-10-04
70370-2040-01 30 CAPSULE in 1 BOTTLE (70370-2040-1) INGREZZA Neurocrine Biosciences, Inc. 2018-12-14
70370-2046-01 1 BLISTER PACK in 1 CARTON (70370-2046-1) / 1 KIT in 1 BLIS... INGREZZA Neurocrine Biosciences, Inc. 2023-08-18
70370-2048-06 1 BLISTER PACK in 1 CARTON (70370-2048-6) / 1 KIT in 1 BLIS... INGREZZA Neurocrine Biosciences, Inc. 2018-12-14
70370-4040-01 30 CAPSULE in 1 BOTTLE (70370-4040-1) INGREZZA Sprinkle Neurocrine Biosciences, Inc. 2024-04-30
70370-4060-01 30 CAPSULE in 1 BOTTLE (70370-4060-1) INGREZZA Sprinkle Neurocrine Biosciences, Inc. 2024-04-30
70370-4080-01 30 CAPSULE in 1 BOTTLE (70370-4080-1) INGREZZA Sprinkle Neurocrine Biosciences, Inc. 2024-04-30
Observed labelers: Neurocrine Biosciences, Inc. (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.